89Zr radiochemistry for positron emission tomography

Medicinal Chemistry

Volumn 7, Issue 5, 2011, Pages 389-394

  Severin, Gregory W ^a   Engle, Jonathan W ^a   Barnhart, Todd E ^a   Nickles, R Jerry ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

89Zr; Desferal; Desferrioxamine; Immuno pet; MAbs; Positron emission tomography; Zirconium 89

Indexed keywords

DEFEROXAMINE; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG; YTTRIUM; ZIRCONIUM; ZIRCONIUM 89; DIAGNOSTIC AGENT; RADIOISOTOPE; RADIOPHARMACEUTICAL AGENT;

CHELATION; CYCLOTRON; HALF LIFE TIME; ISOTOPE LABELING; MOLECULAR IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIOCHEMISTRY; REVIEW; ANIMAL; HUMAN;

ANIMALS; ANTIBODIES, MONOCLONAL; HUMANS; POSITRON-EMISSION TOMOGRAPHY; RADIOCHEMISTRY; RADIOISOTOPES; RADIOPHARMACEUTICALS; ZIRCONIUM;

EID: 80052007520     PISSN: 15734064     EISSN: 18756638     Source Type: Journal    
DOI: 10.2174/157340611796799186     Document Type: Review

References (39)

1. van Dongen, G. A. M. S.; Visser, G. W. M.; Lub-de Hooge, M. N.; de Vries, E. G.; Perk, L. R. Immuno-PET: A Navigator in Monoclonal Antibody Development and Applications. Oncologist, 2007, 12, 1379-1389.
2. Wu, A. M. Antibodies and Antimatter: The Resurgence of Immuno-PET. J. Nucl. Med., 2009, 50, 2-5.
3. Verel, I.; Visser, G. W.; van Dongen, G. A. The promise of immuno-PET in radioimmunotherapy. J. Nucl. Med., 2005, 46 Suppl 1, 164S-171S. (Pubitemid 47619032)
4. Verel, I.; Visser, G. W.; Boellaard, R.; Stigter-van Walsum, M.; Snow, G. B.; van Dongen, G. A. 89Zr immuno-PET: comprehensive procedures for the production of 89Zr-labeled monoclonal antibodies. J. Nucl. Med., 2003, 44, 1271-1281. (Pubitemid 39662684)
5. Miller, M. J. Syntheses and therapeutic potential of hydroxamic acid based siderophores and analogs. Chem Rev, 1989, 89, 1563-1579.
6. Meijs, W. E.; Herscheid, J. D.; Haisma, H. J.; Pinedo, H. M. Evaluation of desferal as a bifunctional chelating agent for labeling antibodies with Zr-89. Int. J. Rad. Appl. Instrum. A Appl. Radiat. Isot., 1992, 43, 1443-1447.
7. Verel, I.; Visser, G. W.; Boellaard, R.; Boerman, O. C.; van Eerd, J.; Snow, G. B.; Lammertsma, A. A.; van Dongen, G. A. Quantitative 89Zr immuno-PET for in vivo scouting of 90Y-labeled monoclonal antibodies in xenograft-bearing nude mice. J. Nucl. Med., 2003, 44, 1663-1670. (Pubitemid 40003744)
8. Holland, J. P.; Sheh, Y.; Lewis, J. S. Standardized methods for the production of high specific-activity zirconium-89. Nucl. Med. Biol., 2009, 36, 729-739.
9. Perk, L. R.; Vosjan, M. J.; Visser, G. W.; Budde, M.; Jurek, P.; Kiefer, G. E.; van Dongen, G. A. p-Isothiocyanatobenzyldesferrioxamine: a new bifunctional chelate for facile radiolabeling of monoclonal antibodies with zirconium-89 for immuno-PET imaging. Eur. J. Nucl. Med. Mol. Imag., 2010, 37, 250-259.
10. Vosjan, M. J.; Perk, L. R.; Visser, G. W.; Budde, M.; Jurek, P.; Kiefer, G. E.; van Dongen, G. A. Conjugation and radiolabeling of monoclonal antibodies with zirconium-89 for PET imaging using the bifunctional chelate p-isothiocyanatobenzyl-desferrioxamine. Nat. Protoc., 2010, 5, 739-743.
11. Meijs, W. E.; Herscheid, J. D. M.; Haisma, H. J.; Wijbrandts, R.; van Langevelde, F.; Van Leuffen, P. J.; Mooy, R.; Pinedo, H. M. Production of highly pure no-carrier added 89Zr for the labelling of antibodies with a positron emitter. Appl Radiat Isot, 1994, 45, 1143-1147.
12. Singh, B. Nuclear Data Sheets for A = 89. Nucl. Data Sheets, 1998, 85, 1-170. (Pubitemid 128181922)
13. Zweit, J.; Downey, S.; Sharma, H. L. Production of no-carrieradded zirconium-89 for positron emission tomography. Int. J. Rad. Appl. Instrum. A Appl. Radiat. Isot., 1991, 42, 199-201.
14. Dutta, B.; Maiti, M.; Lahiri, S. Production of 88, 89Zr by proton induced activation of natY and separation by SLX and LLX. J. Rad. Nuc. Chem., 2009, 281, 663-667.
15. Omara, H. M.; Hassan, K. F.; Kandil, S. A.; Hegazy, F. E.; Saleh, Z. A. Proton induced reactions on 89Y with particular reference to the production of the medically interesting radionuclide 89Zr. Radiochim. Acta., 2009, 97, 467-471.
16. Wenrong, Z.; Qingbiao, S.; Hanlin, L.; Weixiang, Y. Investigation of Y-89 (p, n) Zr-89, Y-89 (p, 2n) Zr-88 and Y-89 (p, pn) Y-88 reactions up to 22 MeV. Chin J Nucl Phys, 1992, 14, 7.
17. La Gamma, A. M.; Nassiff, S. J. Excitation Functions for Deuteron-Induced Reactions on 89Y. Radiochim. Acta., 1973, 19, 161.
18. Dejesus, O. T.; Nickles, R. J. Production and purification of 89Zr, a potential PET antibody label. Int. J. Rad. Appl. Instrum. A. Appl. Radiat. Isot., 1990, 41, 789-790. (Pubitemid 20290490)
19. Herscheid, J. D.; Vos, C. M.; Hoekstra, A. Manganese-52m for direct application: a new 52Fe/52mMn generator based on a hydroxamate resin. Int J Appl Radiat Isot, 1983, 34, 883-886. (Pubitemid 13078312)
20. Holland, J. P.; Divilov, V.; Bander, N. H.; Smith-Jones, P. M.; Larson, S. M.; Lewis, J. S. 89Zr-DFO-J591 for ImmunoPET of Prostate-Specific Membrane Antigen Expression In Vivo. J. Nucl. Med., 2010, 51, 1293-1300.
21. Keberle, H. The Biochemistry of Desferrioxamine and its Relation to Iron Metabolism. Ann. N Y Acad. Sci., 1964, 119, 758-768.
22. Baroncelli, F.; Grossi, G. The complexing power of hydroxamic acids and its effect on the behaviour of organic extractants in the reprocessing of irradiated fuels-I the complexes between benzohydroxamic acid and zirconium, iron (III) and uranium (VI). J. Inorg. Nucl. Chem., 1965, 27, 1085-1092.
23. Takagai, Y.; Takahashi, A.; Yamaguchi, H.; Kubota, T.; Igarashi, S. Adsorption behaviors of high-valence metal ions on desferrioxamine B immobilization nylon 6, 6 chelate fiber under highly acidic conditions. J. Colloid Interface Sci., 2007, 313, 359-362. (Pubitemid 47042755)
24. Perk, L. R.; Visser, O. J.; Stigter-van Walsum, M.; Vosjan, M. J.; Visser, G. W.; Zijlstra, J. M.; Huijgens, P. C.; van Dongen, G. A. Preparation and evaluation of (89) Zr-Zevalin for monitoring of (90) Y-Zevalin biodistribution with positron emission tomography. Eur. J. Nucl. Med. Mol. Imag., 2006, 33, 1337-1345. (Pubitemid 44630790)
25. Meijs, W. E.; Haisma, H. J.; Van der Schors, R.; Wijbrandts, R.; Van den Oever, K.; Klok, R. P.; Pinedo, H. M.; Herscheid, J. D. A facile method for the labeling of proteins with zirconium isotopes. Nucl. Med. Biol., 1996, 23, 439-448. (Pubitemid 26233214)
26. Herscheid, J. D.; Hoekstra, A.; Vos, C. M. N-Succinyldesferrioxamine B: a potential radiopharmaceutical for assessing renal function. Eur. J. Nucl. Med., 1984, 9, 508-510. (Pubitemid 15180322)
27. Tinianow, J. N.; Gill, H. S.; Ogasawara, A.; Flores, J. E.; Vanderbilt, A. N.; Luis, E.; Vandlen, R.; Darwish, M.; Junutula, J. R.; Williams, S. P.; Marik, J. Site-specifically 89Zr-labeled monoclonal antibodies for ImmunoPET. Nucl. Med. Biol., 2010, 37, 289-297.
28. Perk, L. R.; Visser, G. W.; Vosjan, M. J.; Stigter-van Walsum, M.; Tijink, B. M.; Leemans, C. R.; van Dongen, G. A. (89) Zr as a PET surrogate radioisotope for scouting biodistribution of the therapeutic radiometals (90) Y and (177) Lu in tumor-bearing nude mice after coupling to the internalizing antibody cetuximab. J. Nucl. Med., 2005, 46, 1898-1906. (Pubitemid 46196653)
29. Selwyn, R.; Nickles, R. J.; Thomadsen, B. R.; DeWard, L. A.; Micka, J. A. A new internal pair production branching ratio of 90Y: the development of a non-destructive assay for 90Y and 90Sr. Appl. Radiat. Isot., 2007, 65, 318-327. (Pubitemid 44960818)
30. Aerts, H. J. W. L.; Dubois, L.; Perk, L.; Vermaelen, P.; van Dongen, G. A. M. S.; Wouters, B. G.; Lambin, P. Disparity Between In Vivo EGFR Expression and 89Zr-Labeled Cetuximab Uptake Assessed with PET. J. Nucl. Med., 2009, 50, 123-131.
31. Nagengast, W. B.; de Vries, E. G.; Hospers, G. A.; Mulder, N. H.; de Jong, J. R.; Hollema, H.; Brouwers, A. H.; van Dongen, G. A.; Perk, L. R.; Lub-de Hooge, M. N. In Vivo VEGF Imaging with Radiolabeled Bevacizumab in a Human Ovarian Tumor Xenograft. J. Nucl. Med., 2007, 48, 1313-1319. (Pubitemid 47242797)
32. Nagengast, W. B.; de Korte, M. A.; Oude Munnink, T. H.; Timmer-Bosscha, H.; den Dunnen, W. F.; Hollema, H.; de Jong, J. R.; Jensen, M. R.; Quadt, C.; Garcia-Echeverria, C.; van Dongen, G. A. M. S.; Lub-de Hooge, M. N.; Schroder, C. P.; de Vries, E. G. E. 89Zr-Bevacizumab PET of Early Antiangiogenic Tumor Response to Treatment with HSP90 Inhibitor NVP-AUY922. J. Nucl. Med., 2010, 51, 761-767.
33. Holland, J. P.; Caldas-Lopes, E.; Divilov, V.; Longo, V. A.; Taldone, T.; Zatorska, D.; Chiosis, G.; Lewis, J. S. Measuring the Pharmacodynamic Effects of a Novel Hsp90 Inhibitor on HER2 Expression in Mice Using 89Zr-DFO- Trastuzumab. PLoS. ONE, 2010, 5, e8859.
34. Brouwers, A.; Verel, I.; Van Eerd, J.; Visser, G.; Steffens, M.; Oosterwijk, E.; Corstens, F.; Oyen, W.; Van Dongen, G.; Boerman, O. PET radioimmunoscintigraphy of renal cell cancer using 89Zrlabeled cG250 monoclonal antibody in nude rats. Cancer Biother. Radiopharm., 2004, 19, 155-163. (Pubitemid 38685113)
35. Perk, L.; Stigter-van Walsum, M.; Visser, G.; Kloet, R.; Vosjan, M.; Leemans, C.; Giaccone, G.; Albano, R.; Comoglio, P.; van Dongen, G. Quantitative PET imaging of Met-expressing human cancer xenografts with 89Zr-labelled monoclonal antibody DN30. Eur. J. Nucl. Med. Mol. Imaging., 2008, 35, 1857-1867.
36. Oude Munnink, T. H.; Korte, M. A.d.; Nagengast, W. B.; Timmer-Bosscha, H.; Schr̂der, C. P.; Jong, J. R.d.; Dongen, G. A. M. S.v.; Jensen, M. R.; Quadt, C.; Hooge, M. N. L.-d.; Vries, E. G. E.d. 89Zrtrastuzumab PET visualises HER2 downregulation by the HSP90 inhibitor NVP-AUY922 in a human tumour xenograft. Eur. J. Cancer., 2010, 46, 678-684.
37. Borjesson, P. K. E.; Jauw, Y. W. S.; Boellaard, R.; de Bree, R.; Comans, E. F. I.; Roos, J. C.; Castelijns, J. A.; Vosjan, M. J. W. D.; Kummer, J. A.; Leemans, C. R.; Lammertsma, A. A.; van Dongen, G. A. M. S. Performance of Immuno-Positron Emission Tomography with Zirconium-89-Labeled Chimeric Monoclonal Antibody U36 in the Detection of Lymph Node Metastases in Head and Neck Cancer Patients. Clin. Cancer. Res., 2006, 12, 2133-2140.
38. Borjesson, P. K. E.; Jauw, Y. W. S.; de Bree, R.; Roos, J. C.; Castelijns, J. A.; Leemans, C. R.; van Dongen, G. A. M. S.; Boellaard, R. Radiation Dosimetry of 89Zr-Labeled Chimeric Monoclonal Antibody U36 as Used for Immuno-PET in Head and Neck Cancer Patients. J. Nucl. Med., 2009, 50, 1828-1836.
39. Dijkers, E. C.; Oude Munnink, T. H.; Kosterink, J. G.; Brouwers, A. H.; Jager, P. L.; de Jong, J. R.; van Dongen, G. A.; Schroder, C. P.; Lub-de Hooge, M. N.; de Vries, E. G. Biodistribution of 89Zrtrastuzumab and PET Imaging of HER2-Positive Lesions in Patients With Metastatic Breast Cancer. Clin. Pharmacol. Ther., 2010, 87, 586-592.